[Skip to Content]
[Skip to Content Landing]
Views 1,654
Citations 0
Viewpoint
November 2016

The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure–Lowering Trials

Author Affiliations
  • 1Population Health Research Institute, McMaster University, and Hamilton Health Sciences, Hamilton, Ontario, Canada
JAMA Cardiol. 2016;1(8):857-858. doi:10.1001/jamacardio.2016.2169

About 80 randomized clinical trials of blood pressure (BP) lowering involving more than 300 000 participants have been completed. Initial trials involved those with very high BP (stages 2 and 3 hypertension), but recent trials have included participants with lower initial BP levels or those already treated. Interpreting their results should be based on their design, population characteristics, underlying (and untreated) BP levels, interventions, results on main outcomes, and adverse effects. Recent discussions have focused on comparing the recent Heart Outcomes Prevention Evaluation–3 (HOPE-3) trial1 and the Systolic Blood Pressure Intervention Trial (SPRINT),2 but a broader perspective is more appropriate.36

First Page Preview View Large
First page PDF preview
First page PDF preview
×